Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.18 Til Enterprise Value: 1.58 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 92/100

Amgen Inc at Evercore ISI HealthCONx Conference Transcript

Nov 29, 2023 / 02:10PM GMT
Release Date Price: HK$1850
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Pleasure to have Amgen management with us today. I feel like between Shawn, (inaudible) and myself covering Amgen for like 14 years now, I have not seen this type of setup come up in terms of pipeline readouts for Amgen in a long time. So I'm very curious what's on top of your mind, Peter, I want to jump right into it.

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

Great, Umer. Well, thank you for inviting us. With me today, Paul Burton, our Chief Medical Officer; Justin Claeys, our Vice President of Investor Relations. So we're delighted to be here and strong execution driving innovation at speed and scale.

So three points to make there following up on what shared with the group. We've closed Horizon. We've added a Rare Disease business, demonstrating our willingness to pursue the best innovation, whether it's internal or external. And second, to your point, driving our pipeline, rapidly advancing a number of first-in-class,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot